Streetbeat News

DMAC

DiaMedica Therapeutics Inc.

https://www.diamedica.com

Industry

Biotechnology

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Open

4.17

Mkt cap

201M

Volume

183K

High

4.81

P/E Ratio

-8.39

52-wk high

4.95

Low

4.17

Div yield

N/A

52-wk low

2.14

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announced the expansion of its DM199 program into preeclampsia, with a Phase 2 trial starting in Q4 2024 and key results expected in H1 2025. The company will host a conference call on June 27, 2024, and a key opinion leader event on July 29, 2024.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 12:01 pm

DiaMedica Therapeutics reported Q1 2024 GAAP EPS of $(0.14), surpassing the $(0.16) estimate and marking a 30% improvement over last year's $(0.20) per share loss.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 10:39 pm

Craig-Hallum analyst Alexander Nowak assumes coverage on DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy rating and sets a price target of $8.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 5:33 pm

Craig-Hallum analyst Alexander Nowak maintains a Buy rating on DiaMedica Therapeutics (NASDAQ:DMAC) but lowers the price target from $11 to $8.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 6:31 pm

Oppenheimer analyst Francois Brisebois has reiterated an Outperform rating on DiaMedica Therapeutics (NASDAQ:DMAC) but lowered the price target from $7 to $6.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 12:43 pm

DiaMedica Therapeutics (NASDAQ:DMAC) reported its Q4 earnings on March 19, 2024, with an EPS of $-0.14, matching the estimated earnings. The revenue remained unchanged from the same period last year. In the previous quarter, DMAC beat EPS estimates by $0.01, leading to a 7% increase in share price the following day.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 9:25 pm

DiaMedica Therapeutics reported Q3 EPS of $(0.12), surpassing the consensus estimate of $(0.13) by 7.69%. The EPS figure remains the same as the previous year's same quarter.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 9:57 pm

Numerous companies are scheduled to report their earnings on November 13, 2023, both before the bell and after. The list includes a wide range of industries and market caps, with some companies expected to report profits while others are anticipated to report losses. Key companies reporting include Tyson Foods, Henry Schein, and AECOM, with expected earnings per share of $0.29, $1.32, and $0.98 respectively. Other companies like IM Cannabis, Roivant Sciences, and Genius Sports are projected to report losses.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 11:40 am

DiaMedica Therapeutics (NASDAQ:DMAC) is expected to release its quarterly earnings report on Monday, 2023-11-13, with analysts predicting an EPS of $-0.13. Investors are looking for an earnings beat and positive guidance for the next quarter. Historically, DMAC's stock price has reacted to both earnings outcomes and guidance. Last quarter, DMAC beat the EPS estimate by $0.02, leading to a 4.4% stock price increase the following day. Over the last year, DMAC shares have risen by 101.7%, trading at $2.35 as of November 09.

Portfolio Pulse from Benzinga Insights

November 10, 2023 | 5:02 pm

DiaMedica Therapeutics reported Q2 losses of $(0.16) per share, beating the analyst consensus estimate of $(0.18) by 11.11%. However, this is a 23.08% decrease over losses of $(0.13) per share from the same period last year.

Portfolio Pulse from vinayak@benzinga.com

August 14, 2023 | 8:48 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.